The Thrombopoietin Receptor Agonist Eltrombopag Inhibits Human Cytomegalovirus Replication Via Iron Chelation

The thrombopoietin receptor agonist eltrombopag was successfully used against human cytomegalovirus (HCMV)-associated thrombocytopenia refractory to immunomodulatory and antiviral drugs. These effects were ascribed to the effects of eltrombopag on megakaryocytes. Here, we tested whether eltrombopag...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Cells
Prif Awduron: Vogel, Jens-Uwe, Schmidt, Sophie, Schmidt, Daniel, Rothweiler, Florian, Koch, Benjamin, Baer, Patrick, Rabenau, Holger, Michel, Detlef, Stamminger, Thomas, Michaelis, Martin, Cinatl, Jindrich
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: MDPI 2019
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7017049/
https://ncbi.nlm.nih.gov/pubmed/31861948
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cells9010031
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg